C. neoformans Galactoxylomannan (GalXM) Production Service

C. neoformans Galactoxylomannan (GalXM) Production Service at CD BioGlyco

CD BioGlyco has been exploring the field of Carbohydrate-based Vaccine Development for many years. Throughout this system, we have focused on vaccine development and antigen production research. GalXM is an important component in the field of carbohydrate-based antifungal antigens. We provide full GalXM production services.

We have developed an approach to produce GalXM utilizing the C. neoformans.
- First, two different portions of the capsule are prepared by irradiation of C. neoformans.
- Then the washing and irradiation are continued for 20 min, stripping off the denser regions of the capsule. GalXM is isolated from the supernatant after homogenization of the cell wall to produce GalXM of sufficient purity for structural studies and subsequent research.
- Next, we analyze the GalXM main chain structure by GC/MS of each O derivative of monosaccharomethyl glycosides produced by acidic methane hydrolysis and conclude that the GalXM main chain consists of galactofuranose and a small amount of galactofuranose. The specific compositions are 22% xylose, 29% mannose, and 50% galactofuranose.
In addition to this, we also perform an immune response testing service on it. GalXM is essentially non-immunogenic and produces an immune response in mice. Therefore, we couple GalXM with a protein carrier to detect the immune response.
GalXM acts as a virulence factor and produces an antibody response in its interaction with the host. Because of the effective and sustained antibody response it generates, we also provide for the development of related vaccines.

Fig.1 GalXM antigen production and vaccine development process. (CD BioGlyco)

Publication

Technology: Use of capsular components as antifungal targets and vaccines.

Journal: Advances in Applied Microbiology.

IF: 5.515

Published: 2009

Results: Given the critical role of capsules in toxicity, the authors have undertaken considerable efforts to develop antibodies and vaccines against this structure. Two general approaches have been taken. First, many monoclonal antibodies have been developed to target the podocarp component as a form of passive immunization. Studies of these monoclonal antibodies have shown that the function of antibodies against novel clostridia is extremely complex, as some immunoglobulins protect while others do not, and others may even lead to the enhancement of disease. A second approach is the use of podocarp polysaccharides or capsule mimetic structures as protective active vaccines. In vaccine development, the capsule is used as an antifungal target, and podocarp components are used to develop the vaccine. GalXM acts as an antigen and consists of two M2 repeat sequences and a mannose residue that is strongly recognized by two different IgMs at the same time.

Fig.2 Basic GalXM structure. (Zaragoza, et al., 2009)

Applications

GalXM is a complex polysaccharide produced by the human pathogenic fungus C. neoformans that can be used to characterize fungal disease.
GalXM can be used to develop antifungal vaccines.
GalXM can be used to study the process of certain immune responses in the human body.

Advantages

Our team has a specialized knowledge base in the development of antifungal vaccines and many years of experience in the production of antigens.
We offer custom antigen production services according to client needs.

CD BioGlyco has extensive experience in the synthesis of antigens and the development of vaccines. We not only provide our clients with the synthesis of specific antigens but also with the structural analysis of antigens. With our advanced technology and excellent research team, we are fully capable of meeting your requirements. We encourage our clients to contact us as we eagerly look forward to the opportunity to assist them.

Reference

Zaragoza, O.; et al. The capsule of the fungal pathogen Cryptococcus neoformans. Advances in Applied Microbiology. 2009, 68: 133-216.

This service is for Research Use Only, not intended for any clinical use.